Brentuximab vedotin also known as SGN-35, is the second ADC drug received market approval by the FDA in 2011 for the treatment of r/r CD30 positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.